Dementia Discovery Fund Closes Second Fund at $269M, Bringing Total Raised to Over $550M
The Dementia Discovery Fund (DDF), managed by SV Health Investors, has closed its second fund, DDF-2, at $269 million, bringing total capital raised across its funds to over $550 million. According to DDF, this makes it the largest global venture capital platform exclusively focused on developing and enabling therapeutics for dementia.
Backers of DDF-2 include returning institutional and strategic investors—Gates Ventures, AARP, British Business Bank, Bristol Myers Squibb, Eli Lilly, and Pfizer—with new participation from the Alzheimer’s Association. DDF-2 has already deployed capital into four companies and plans to build a 10–15 company portfolio across the US, UK, and Europe. Since its inception in 2015, DDF has supported 19 companies, including 11 with clinical-stage assets, and over 2,000 patients have received experimental treatments from DDF-supported programs.
In a 2024 interview with BiopharmaTrend, Laurence Barker, Partner at SV Health Investors and DDF lead, outlined the fund’s strategic commitment to precision neuroscience as an approach modeled on the successes of precision oncology. He emphasized the need for data-driven strategies, including AI-informed drug discovery and combination therapies, to overcome the high failure rate in neurology trials.
DDF’s portfolio illustrates this with companies like Alchemab Therapeutics, which uses AI to identify protective antibodies in resilient individuals, and Cerevance, which targets neuroinflammatory pathways and has partnered with Merck. According to Barker, such efforts reflect a paradigm shift from monotherapies to synergistic interventions tailored to molecular and patient-level profiles.
Topics: Novel Therapeutics
